Pharmaceutical Technology
FEBRUARY 5, 2023
The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Trodelvy (sacituzumab govitecan-hziy) to treat unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer adult patients.
JAMA Internal Medicine
FEBRUARY 5, 2023
This cross-sectional study examines the death rates among active and nonactive physicians aged 45 to 84 years
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
FEBRUARY 5, 2023
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Cyprus?
JAMA Internal Medicine
FEBRUARY 5, 2023
This comparative effectiveness study evaluates cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in adults with type 2 diabetes overall and at varying baseline HbA1c levels
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
Roots Analysis
FEBRUARY 5, 2023
Modified T-cell receptors or TCR therapies is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Structurally, TCR is a heterodimer comprising of two different polypeptide chains, namely the α-chain and β-chain.
The Pharma Data
FEBRUARY 5, 2023
A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology (IIN) at Northwestern University.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
JAMA Internal Medicine
FEBRUARY 5, 2023
This prospective cohort study investigates the association between healthy lifestyle factors prior to SARS-CoV-2 infection and risk of post–COVID-19 condition
JAMA Internal Medicine
FEBRUARY 5, 2023
This randomized clinical trial examines the safety and efficacy of reducing or stopping medications among inpatients 50 years or older
The Pharma Data
FEBRUARY 5, 2023
TAKHZYRO is the First and Only Prophylaxis Treatment Approved in the U.S.
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Drug Patent Watch
FEBRUARY 5, 2023
NEXAVAR (sorafenib tosylate) Bayer hlthcare Patent: 8,618,141 Expiration: Feb 11, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of February 5, 2023 appeared first on DrugPatentWatch - Make Better Decisions. Patent Expiration
The Pharma Data
FEBRUARY 5, 2023
The World Health Organization (WHO) released a new Global Breast Cancer Initiative Framework today providing a roadmap to attain the targets to save 2.5 million lives from breast cancer by 2040. The new Framework launched ahead of the World Cancer Day campaign marked tomorrow, recommends to countries to implement the three pillars of health promotion for early detection, timely diagnosis and comprehensive management of breast cancer to reach the targets. There are more than 2.3
Expert insights. Personalized for you.
264 
Let's personalize your content